New mutations and pathogenesis of myeloproliferative neoplasms

Blood

Volumn 118, Issue 7, 2011, Pages 1723-1735

  Vainchenker, William ^a,b   Delhommeau, François ^a,c   Constantinescu, Stefan N ^d,e   Bernard, Olivier A ^a,b,f  

^a INSTITUT GUSTAVE ROUSSY   (France)

^b UNIVERSITÉ PARIS SACLAY   (France)

^c SORBONNE UNIVERSITÉ   (France)

^d LUDWIG INSTITUTE FOR CANCER RESEARCH   (Belgium)

^e DE DUVE INSTITUTE   (Belgium)

^f INSERM   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ASXL1 PROTEIN; DEHYDROGENASE 1; DEHYDROGENASE 2; ENHANCER OF ZESTE HOMOLOG 1; IKAROS TRANSCRIPTION FACTOR 1 PROTEIN; JANUS KINASE 2; K RAS PROTEIN; OXIDOREDUCTASE; PROTEIN; PROTEIN P53; SUPPRESSOR OF CYTOKINE SIGNALING 1; SUPPRESSOR OF CYTOKINE SIGNALING 2; SUPPRESSOR OF CYTOKINE SIGNALING 3; TEN ELEVEN TRANSLOCATION2 PROTEIN; TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR EZH2; TRANSCRIPTION FACTOR RUNX1; UNCLASSIFIED DRUG;

ACUTE GRANULOCYTIC LEUKEMIA; B CELL LYMPHOMA; CANCER GROWTH; CARCINOGENESIS; CELL ACTIVATION; EPIGENETICS; EXON; GENE DELETION; GENE FUNCTION; GENE MUTATION; GENETIC REGULATION; HEMATOPOIESIS; LEUKEMIA; MYELOFIBROSIS; MYELOPROLIFERATIVE DISORDER; ONCOGENE N RAS; PATHOGENESIS; POLYCYTHEMIA VERA; PRIORITY JOURNAL; REVIEW; SIGNAL TRANSDUCTION; THROMBOCYTHEMIA;

EID: 80051931772     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2011-02-292102     Document Type: Review

References (198)

1. DameshekW. Some speculations on the myeloproliferative syndromes. Blood. 1951;6(4):372-375.
2. Tefferi A., Thiele J., Vardiman J.W. The 2008 World Health Organization classification system for myeloproliferative neoplasms: Order out of chaos. Cancer. 2009;115(17):3842-3847.
3. Delhommeau F., Pisani D.F., James C., Casadevall N., Constantinescu S., VainchenkerW. Oncogenic mechanisms in myeloproliferative disorders. Cell Mol Life Sci. 2006;63(24):2939-2953. (Pubitemid 46072300)
4. Campbell P.J., Green AR. The myeloproliferative disorders. N Engl J Med. 2006 7;355(23):2452-2466.
5. Kralovics R., Guan Y., Prchal J.T. Acquired uniparental disomy of chromosome 9p is a frequent stem cell defect in polycythemia vera. Exp Hematol. 2002;30(3):229-236. (Pubitemid 34203729)
6. James C., Ugo V., Le Couedic J.P., et al. A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera. Nature. 2005;434(7037):1144-1148. (Pubitemid 40663494)
7. Baxter E.J., Scott L.M., Campbell P.J., et al. Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders. Lancet. 2005;365(9464):1054-1061. (Pubitemid 40386783)
8. Kralovics R., Passamonti F., Buser A.S., et al. A gain-of-function mutation of JAK2 in myeloproliferative disorders. N Engl J Med. 2005;352(17):1779-1790. (Pubitemid 40570926)
9. Levine R.L., Wadleigh M., Cools J., et al. Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. Cancer Cell. 2005;7(4):387-397. (Pubitemid 40544655)
10. Saharinen P., Silvennoinen O. The pseudokinase domain is required for suppression of basal activity of Jak2 and Jak3 tyrosine kinases and for cytokine-inducible activation of signal transduction. J Biol Chem. 2002;277(49):47954-44773
11. Scott L.M., Tong W., Levine R.L., et al. JAK2 exon 12 mutations in polycythemia vera and idiopathic erythrocytosis. N Engl J Med. 2007;356(5):459-468. (Pubitemid 46193073)
12. Pietra D., Li S., Brisci A., et al. Somatic mutations of JAK2 exon 12 in patients with JAK2 (V617F)-negative myeloproliferative disorders. Blood. 2008;111(3):1686-1689. (Pubitemid 351213460)
13. Pikman Y., Lee B.H., Mercher T., et al. MPLW515L is a novel somatic activating mutation in myelofibrosis with myeloid metaplasia. PLoS Med. 2006;3(7):e270.
14. Beer P.A., Campbell P.J., Scott L.M., et al. MPL mutations in myeloproliferative disorders: Analysis of the PT-1 cohort. Blood. 2008;112(1):141-149.
15. Boyd E.M., Bench A.J., Goday-Fernandez A., et al. Clinical utility of routine MPL exon 10 analysis in the diagnosis of essential thrombocythaemia and primary myelofibrosis. Br J Haematol. 2010;149(2):250-257.
16. Chaligné R., Tonetti C., Besancenot R., et al. New mutations of MPL in primitive myelofibrosis: Only the MPL W515 mutations promote a G1/S-phase transition. Leukemia. 2008;22(8):1557-1566.
17. Oh S.T., Simonds E.F., Jones C., et al. Novel mutations in the inhibitory adaptor protein LNK drive JAK-STAT signaling in patients with myeloproliferative neoplasms. Blood. 2010;116(6):988-992.
18. Pardanani A., Lasho T., Finke C., Oh S.T., Gotlib J., Tefferi A. LNK mutation studies in blast-phase myeloproliferative neoplasms, and in chronic-phase disease with TET2, IDH, JAK2 or MPL mutations. Leukemia. 2010;24(10):1713-1718.
19. Lasho T.L., Pardanani A., Tefferi A. LNK mutations in JAK2 mutation-negative erythrocytosis. N Engl J Med. 2010;363(12):1189-1190.
20. Grand F.H., Hidalgo-Curtis C.E., Ernst T., et al. Frequent CBL mutations associated with 11q acquired uniparental disomy in myeloproliferative neoplasms. Blood. 2009;113(24):6182-6192.
21. Beer P.A., Delhommeau F., LeCouedic J.P., et al. Two routes to leukemic transformation after a JAK2 mutation-positive myeloproliferative neoplasm. Blood. 2010;115(14):2891-2900.
22. Jost E, do ON, Dahl E, et al. Epigenetic alterations complement mutation of JAK2 tyrosine kinase in patients with BCR/ABL-negative myeloproliferative disorders. Leukemia. 2007;21(3):505-510.
23. Teofili L., Martini M., Cenci T., et al. Epigenetic alteration of SOCS family members is a possible pathogenetic mechanism in JAK2 wild type myeloproliferative diseases. Int J Cancer. 2008; 123(7):1586-1592.
24. Quentmeier H., Geffers R., Jost E., et al. SOCS2: Inhibitor of JAK2V617F-mediated signal transduction. Leukemia. 2008;22(12):2169-2175.
25. Suessmuth Y., Elliott J., Percy M.J., et al. A new polycythaemia vera-associated SOCS3 SH2 mutant (SOCS3F136L) cannot regulate erythropoietin responses. Br J Haematol. 2009;147(4):450-458.
26. Fourouclas N., Li J., Gilby D.C., et al. Methylation of the suppressor of cytokine signaling 3 gene (SOCS3) in myeloproliferative disorders. Haematologica. 2008;93(11):1635-1644.
27. Chaligné R., Tonetti C., Besancenot R., et al. SOCS3 inhibits TPO-stimulated, but not spontaneous, megakaryocytic growth in primary myelofibrosis. Leukemia. 2009;23(6):1186-1190.
28. Kawamata N., Ogawa S., Yamamoto G., et al. Genetic profiling of myeloproliferative disorders by single-nucleotide polymorphism oligonucleotide microarray. Exp Hematol. 2008;36(11):1471-1479.
29. Stegelmann F., Bullinger L., Griesshammer M., et al. High-resolution single-nucleotide polymorphism array-profiling in myeloproliferative neoplasms identifies novel genomic aberrations. Haematologica. 2010;95(4):666-669.
30. Langemeijer S.M., Kuiper R.P., Berends M., et al. Acquired mutations in TET2 are common in myelodysplastic syndromes. Nat Genet. 2009;41(7):838-842.
31. Tefferi A., Levine R.L., Lim K.H., et al. Frequent TET2 mutations in systemic mastocytosis: Clinical, KITD816V and FIP1L1-PDGFRA correlates. Leukemia. 2009;23(5):900-904.
32. Delhommeau F., Dupont S., Della Valle V., et al. Mutation in TET2 in myeloid cancers. N Engl J Med. 2009;360(22):2289-2301.
33. Abdel-Wahab O., Mullally A., Hedvat C., et al. Genetic characterization of TET1, TET2, and TET3 alterations in myeloid malignancies. Blood. 2009;114(1):144-147.
34. Carbuccia N., Murati A., Trouplin V., et al. Mutations of ASXL1 gene in myeloproliferative neoplasms. Leukemia. 2009;23(11):2183-2186.
35. Tefferi A. Novel mutations and their functional and clinical relevance in myeloproliferative neoplasms: JAK2, MPL, TET2, ASXL1, CBL, IDH and IKZF1. Leukemia. 2010;24(6):1128-1138.
36. Ernst T., Chase A.J., Score J., et al. Inactivating mutations of the histone methyltransferase gene EZH2 in myeloid disorders. Nat Genet. 2010;42(8):722-726.
37. Nikoloski G., Langemeijer S.M., Kuiper R.P., et al. Somatic mutations of the histone methyltransferase gene EZH2 in myelodysplastic syndromes. Nat Genet. 2010;42(8):665-667.
38. Makishima H., Jankowska A.M., Tiu R.V., et al. Novel homo- and hemizygous mutations in EZH2 in myeloid malignancies. Leukemia. 2010;24(10):1799-1804.
39. Jäger R., Gisslinger H., Passamonti F., et al. Deletions of the transcription factor Ikaros in myeloproliferative neoplasms. Leukemia. 2010;24(7):1290-1298.
40. Ding Y., Harada Y., Imagawa J., Kimura A., Harada H. AML1/RUNX1 point mutation possibly promotes leukemic transformation in myeloproliferative neoplasms. Blood. 2009;114(25):5201-5205.
41. Harutyunyan A., Klampfl T., Cazzola M., Kralovics R. p53 lesions in leukemic transformation. N Engl J Med. 2011;364(5):488-490.
42. Pardanani A., Lasho T.L., Finke C.M., Mai M., McClure R.F., Tefferi A. IDH1 and IDH2 mutation analysis in chronic- and blast-phase myeloproliferative neoplasms. Leukemia. 2010;24(6):1146-1151.
43. Royer Y., Staerk J., Costuleanu M., Courtoy P.J., Constantinescu S.N. Janus kinases affect thrombopoietin receptor cell surface localization and stability. J Biol Chem. 2005;280(29):27251-27261. (Pubitemid 41040765)
44. Meenhuis A., Irandoust M., Wolfler A., Roovers O., Valkhof M., Touw I.P. Janus kinases promote cell-surface expression and provoke autonomous signalling from routing-defective G-CSF receptors. Biochem J. 2009;417(3):737-746.
45. Lu X., Huang L.J., Lodish H.F. Dimerization by a cytokine receptor is necessary for constitutive activation of JAK2V617F. J Biol Chem. 2008;283(9):5258-5266.
46. Lindauer K., Loerting T., Liedl K.R., Kroemer R.T. Prediction of the structure of human Janus kinase 2 (JAK2) comprising the two carboxy-terminal domains reveals a mechanism for autoregulation. Protein Eng. 2001;14(1):27-37. (Pubitemid 32318935)
47. Plo I., Vainchenker W. Molecular and genetic bases of myeloproliferative disorders: Questions and perspectives. Clin Lymphoma Myeloma. 2009;9(Suppl 3):S329-S339.
48. Shi S., Calhoun H.C., Xia F., Li J., Le L., Li W.X. JAK signaling globally counteracts heterochromatic gene silencing. Nat Genet. 2006;38(9):1071-1076. (Pubitemid 44325935)
49. Shi S., Larson K., Guo D., et al. Drosophila STAT is required for directly maintaining HP1 localization and heterochromatin stability. Nat Cell Biol. 2008;10(4):489-496.
50. Dawson M.A., Bannister A.J., Gottgens B., et al. JAK2 phosphorylates histone H3Y41 and excludes HP1alpha from chromatin. Nature. 2009; 461(7265):819-822.
51. Liu F., Zhao X., Perna F., et al. JAK2V617F-mediated phosphorylation of PRMT5 downregulates its methyltransferase activity and promotes myeloproliferation. Cancer Cell. 2011;19(2):283-294.
52. Dusa A., Mouton C., Pecquet C., Herman M., Constantinescu S.N. JAK2 V617F constitutive activation requires JH2 residue F595: A pseudokinase domain target for specific inhibitors. PLoS One. 2010;5(6):e11157.
53. Passamonti F., Elena C., Schnittger S., et al. Molecular and clinical features of the myeloproliferative neoplasm associated with JAK2 exon 12 mutations [published online ahead of print January 11, 2011]. Blood. doi:10.1182/blood-2010-11-316810
54. Staerk J., Lacout C., Sato T., Smith S.O., VainchenkerW., Constantinescu S.N.An amphipathic motif at the transmembrane-cytoplasmic junction prevents autonomous activation of the thrombopoietin receptor. Blood. 2006;107(5):1864-1871. (Pubitemid 43289364)
55. Pecquet C., Staerk J., Chaligne R., et al. Induction of myeloproliferative disorder and myelofibrosis by thrombopoietin receptor W515 mutants is mediated by cytosolic tyrosine 112 of the receptor. Blood. 2010;115(5):1037-1048.
56. Pietra D., Brisci A., Rumi E., et al. Deep sequencing reveals double mutations in cis of MPL exon 10 in myeloproliferative neoplasms. Haematologica. 2011;96(4):607-611.
57. Lacout C., Pisani D.F., Tulliez M., Gachelin F.M., Vainchenker W., Villeval J.L. JAK2V617F expression in murine hematopoietic cells leads to MPD mimicking human PV with secondary myelofibrosis. Blood. 2006;108(5):1652-1660. (Pubitemid 44316134)
58. .Wernig G., Mercher T., Okabe R., Levine R.L., Lee B.H., Gilliland D.G. Expression of Jak2V617F causes a polycythemia vera-like disease with associated myelofibrosis in a murine bone marrow transplant model. Blood. 2006;107(11):4274-4281. (Pubitemid 43801351)
59. Mullally A., Lane S.W., Ball B., et al. Physiological Jak2V617F expression causes a lethal myeloproliferative neoplasm with differential effects on hematopoietic stem and progenitor cells. Cancer Cell. 2010;17(6):584-596.
60. Marty C., Lacout C., Martin A., et al. Myeloproliferative neoplasm induced by constitutive expression of JAK2V617F in knock-in mice. Blood. 2010;116(5):783-787.
61. Tiedt R., Hao-Shen H., Sobas M.A., et al. Ratio of mutant JAK2-V617F to wild-type Jak2 determines the MPD phenotypes in transgenic mice. Blood. 2008;111(8):3931-3940.
62. Akada H., Yan D., Zou H., Fiering S., Hutchison R.E., Mohi M.G. Conditional expression of heterozygous or homozygous Jak2V617F from its endogenous promoter induces a polycythemia vera-like disease. Blood. 2010;115(17):3589-3597.
63. Xing S., Wanting T.H., Zhao W., et al. Transgenic expression of JAK2V617F causes myeloproliferative disorders in mice. Blood. 2008;111(10):5109-5117.
64. Li J., Spensberger D., Ahn J.S., et al. JAK2 V617F impairs hematopoietic stem cell function in a conditional knock-in mouse model of JAK2 V617F-positive essential thrombocythemia. Blood. 2010;116(9):1528-1538.
65. Scott L.M., Scott M.A., Campbell P.J., Green A.R. Progenitors homozygous for the V617F mutation occur in most patients with polycythemia vera, but not essential thrombocythemia. Blood. 2006;108(7):2435-2437. (Pubitemid 44497530)
66. Dupont S., Masse A., James C., et al. The JAK2 617V>F mutation triggers erythropoietin hypersensitivity and terminal erythroid amplification in primary cells from patients with polycythemia vera. Blood. 2007;110(3):1013- 1021. (Pubitemid 47267441)
67. Bumm T.G., Elsea C., Corbin A.S., et al. Characterization of murine JAK2V617F-positive myeloproliferative disease. Cancer Res. 2006;66(23):11156- 11165. (Pubitemid 46009942)
68. Zaleskas V.M., Krause D.S., Lazarides K., et al. Molecular pathogenesis and therapy of polycythemia induced in mice by JAK2 V617F. PLoS One. 2006;1(1):e18.
69. Chen E., Beer P.A., Godfrey A.L., et al. Distinct clinical phenotypes associated with JAK2V617F reflect differential STAT1 signaling. Cancer Cell. 2010;18(5):524-535.
70. Rudd C.E. Lnk adaptor: Novel negative regulator of B cell lymphopoiesis. Sci STKE. 2001;2001(85):pe1.
71. Tong W., Zhang J., Lodish H.F. Lnk inhibits erythropoiesis and Epo-dependent JAK2 activation and downstream signaling pathways. Blood. 2005;105(12):4604-4612. (Pubitemid 40807278)
72. Tong W., Lodish H.F. Lnk inhibits Tpo-mpl signaling and Tpo-mediated megakaryocytopoiesis. J Exp Med. 2004;200(5):569-580. (Pubitemid 39258306)
73. Simon C., Dondi E., Chaix A., et al. Lnk adaptor protein down-regulates specific Kit-induced signaling pathways in primary mast cells. Blood. 2008;112(10):4039-4047.
74. Takaki S., Morita H., Tezuka Y., Takatsu K. Enhanced hematopoiesis by hematopoietic progenitor cells lacking intracellular adaptor protein, Lnk. J Exp Med. 2002;195(2):151-160. (Pubitemid 34461259)
75. Seita J., Ema H., Ooehara J., et al. Lnk negatively regulates self-renewal of hematopoietic stem cells by modifying thrombopoietin-mediated signal transduction. Proc Natl Acad Sci U S A. 2007;104(7):2349-2354 (Pubitemid 46391400)
76. Yoshihara H., Arai F., Hosokawa K., et al. Thrombopoietin/ MPL signaling regulates hematopoietic stem cell quiescence and interaction with the osteoblastic niche. Cell Stem Cell. 2007;1(6):685-697. (Pubitemid 350215333)
77. Qian H., Buza-Vidas N., Hyland C.D., et al. Critical role of thrombopoietin in maintaining adult quiescent hematopoietic stem cells. Cell Stem Cell. 2007;1(6):671-684. (Pubitemid 350215331)
78. Velazquez L., Cheng A.M., Fleming H.E., et al. Cytokine signaling and hematopoietic homeostasis are disrupted in Lnk-deficient mice. J Exp Med. 2002;195(12):1599-1611. (Pubitemid 34666073)
79. Gery S., Gueller S., Chumakova K., Kawamata N., Liu L., Koeffler H.P. Adaptor protein Lnk negatively regulates the mutant MPL, MPLW515L associated with myeloproliferative disorders. Blood. 2007;110(9):3360-3364. (Pubitemid 350106330)
80. Bersenev A., Wu C., Balcerek J., et al. Lnk constrains myeloproliferative diseases in mice. J Clin Invest. 2010;120(6):2058-2069.
81. Baran-Marszak F., Magdoud H., Desterke C., et al. Expression level and differential JAK2-V617F-binding of the adaptor protein Lnk regulates JAK2-mediated signals in myeloproliferative neoplasms. Blood. 2010;116(26):5961-5971.
82. Schmidt M.H., Dikic I. The Cbl interactome and its functions. Nat Rev Mol Cell Biol. 2005;6(12):907-918. (Pubitemid 41778710)
83. Saur S.J., Sangkhae V., Geddis A.E., Kaushansky K., Hitchcock I.S. Ubiquitination and degradation of the thrombopoietin receptor c-Mpl. Blood. 2010;115(6):1254-1263.
84. Bacher U., Haferlach C., Schnittger S., Kohlmann A., Kern W., Haferlach T. Mutations of the TET2 and CBL genes: Novel molecular markers in myeloid malignancies. Ann Hematol. 2010;89(7):643-652.
85. Kales S.C., Ryan P.E., Nau M.M., Lipkowitz S. Cbl and human myeloid neoplasms: The Cbl oncogene comes of age. Cancer Res. 2010;70(12):4789-4794.
86. Rathinam C., Thien C.B., Flavell R.A., Langdon W.Y. Myeloid leukemia development in c-Cbl RING finger mutant mice is dependent on FLT3 signaling. Cancer Cell. 2010;18(4):341-352.
87. Ogawa S., Sanada M., Shih L.Y., et al. Gain-of-function c-CBL mutations associated with uniparental disomy of 11q in myeloid neoplasms. Cell Cycle. 2010;9(6):1051-1056.
88. Sanada M., Suzuki T., Shih L.Y., et al. Gain-of-function of mutated C-CBL tumour suppressor in myeloid neoplasms. Nature. 2009;460(7257):904-908.
89. Naramura M., Nandwani N., Gu H., Band V., Band H. Rapidly fatal myeloproliferative disorders in mice with deletion of Casitas B-cell lymphoma (Cbl) and Cbl-b in hematopoietic stem cells. Proc Natl Acad Sci U S A. 2010;107(37):16274-16279.
90. Krebs D.L., Hilton D.J. SOCS: Physiological suppressors of cytokine signaling. J Cell Sci. 2000;113(Pt 16):2813-2819.
91. Melzner I., Bucur A.J., Bruderlein S., et al. Biallelic mutation of SOCS-1 impairs JAK2 degradation and sustains phospho-JAK2 action in the MedB-1 mediastinal lymphoma line. Blood. 2005;105(6):2535-2542. (Pubitemid 40387056)
92. Calabrese V., Mallette F.A., Deschenes-Simard X., et al. SOCS1 links cytokine signaling to p53 and senescence. Mol Cell. 2009;36(5):754-767.
93. Haan S., Wuller S., Kaczor J., et al. SOCSmediated downregulation of mutant Jak2 (V617F, T875N and K539L) counteracts cytokine-independent signaling. Oncogene. 2009;28(34):3069-3080.
94. Hookham M.B., Elliott J., Suessmuth Y., et al. The myeloproliferative disorder-associated JAK2 V617F mutant escapes negative regulation by suppressor of cytokine signaling 3. Blood. 2007;109(11):4924-4929. (Pubitemid 46827790)
95. Elliott J., Suessmuth Y., Scott L.M., et al. SOCS3 tyrosine phosphorylation as a potential biomarker for myeloproliferative neoplasms associated with mutant JAK2 kinases. Haematologica. 2009;94(4):576-580.
96. Najean Y., Rain J.D. The very long-term evolution of polycythemia vera: An analysis of 318 patients initially treated by phlebotomy or 32P between 1969 and 1981. Semin Hematol. 1997;34(1):6-16. (Pubitemid 27063137)
97. Campbell P.J., Baxter E.J., Beer P.A., et al. Mutation of JAK2 in the myeloproliferative disorders: Timing, clonality studies, cytogenetic associations, and role in leukemic transformation. Blood. 2006;108(10):3548- 3555.
98. Mesa R.A., Li C.Y., Ketterling R.P., Schroeder G.S., Knudson R.A., Tefferi A. Leukemic transformation in myelofibrosis with myeloid metaplasia: A single-institution experience with 91 cases. Blood. 2005;105(3):973-977. (Pubitemid 40170863)
99. Thoennissen N.H., Krug U.O., Lee D.H., et al. Prevalence and prognostic impact of allelic imbalances associated with leukemic transformation of Philadelphia chromosome-negative myeloproliferative neoplasms. Blood. 2010;115(14):2882-2890.
100. Dang L., Jin S., Su S.M. IDH mutations in glioma and acute myeloid leukemia. Trends Mol Med. 2010;16(9):387-397.
101. Yen K.E., Bittinger M.A., Su S.M., Fantin V.R. Cancerassociated IDH mutations: Biomarker and therapeutic opportunities. Oncogene. 2010;29(49):6409-6417.
102. Abbas S., Lugthart S., Kavelaars F.G., et al. Acquired mutations in the genes encoding IDH1 and IDH2 both are recurrent aberrations in acute myeloid leukemia: Prevalence and prognostic value. Blood. 2010;116(12):2122-2126.
103. Schnittger S., Haferlach C., Ulke M., Alpermann T., Kern W., Haferlach T. IDH1 mutations are detected in 6.6% of 1414 AML patients and are associated with intermediate risk karyotype and unfavorable prognosis in adults younger than 60 years and unmutated NPM1 status. Blood. 2010;116(25):5486-5496.
104. Figueroa M.E., Abdel-Wahab O., Lu C., et al. Leukemic IDH1 and IDH2 mutations result in a hypermethylation phenotype, disrupt TET2 function, and impair hematopoietic differentiation. Cancer Cell. 2010;18(6):553-567.
105. Georgopoulos K. Haematopoietic cell-fate decisions, chromatin regulation and ikaros. Nat Rev Immunol. 2002;2(3):162-174. (Pubitemid 37328763)
106. Mullighan C., Downing J. Ikaros and acute leukemia. Leuk Lymphoma. 2008;49(5):847-849. (Pubitemid 351942735)
107. Haferlach C., Dicker F., Herholz H., Schnittger S., Kern W., Haferlach T. Mutations of the TP53 gene in acute myeloid leukemia are strongly associated with a complex aberrant karyotype. Leukemia. 2008;22(8):1539-1541.
108. Beer P.A., Ortmann C.A., Campbell P.J., Green A.R. Independently acquired biallelic JAK2 mutations are present in a minority of patients with essential thrombocythemia. Blood. 2010;116(6):1013-1014.
109. Beer P.A., Ortmann C.A., Stegelmann F., et al. Molecular mechanisms associated with leukemic transformation of MPL-mutant myeloproliferative neoplasms. Haematologica. 2010;95(12):2153-2156.
110. Harada Y., Harada H. Molecular pathways mediating MDS/AML with focus on AML1/RUNX1 point mutations. J Cell Physiol. 2009;220(1):16-20.
111. Bellanné-Chantelot C., Chaumarel I., Labopin M., et al. Genetic and clinical implications of the Val617Phe JAK2 mutation in 72 families with myeloproliferative disorders. Blood. 2006;108(1):346-352. (Pubitemid 43990648)
112. Olcaydu D., Rumi E., Harutyunyan A., et al. The role of the JAK2 GGCC haplotype and the TET2 gene in familial myeloproliferative neoplasms. Haematologica. 2011;96(3):367-374.
113. Posthuma H.L., Skoda R.C., Jacob F.A., Van der Maas A.P., Valk P.J., Posthuma E.F. Hereditary thrombocytosis not as innocent as thought? Development into acute leukemia and myelofibrosis. Blood. 2010;116(17):3375-3376.
114. Levine R.L., Belisle C., Wadleigh M., et al. Xinactivation-based clonality analysis and quantitative JAK2V617F assessment reveal a strong association between clonality and JAK2V617F in PV but not ET/MMM, and identifies a subset of JAK2V617F-negative ET and MMM patients with clonal hematopoiesis. Blood. 2006;107(10):4139-4141. (Pubitemid 43726824)
115. Nussenzveig R.H., Swierczek S.I., Jelinek J., et al. Polycythemia vera is not initiated by JAK2V617F mutation. Exp Hematol. 2007;35(1):32-38.
116. Kralovics R., Teo S.S., Li S., et al. Acquisition of the V617F mutation of JAK2 is a late genetic event in a subset of patients with myeloproliferative disorders. Blood. 2006;108(4):1377-1380. (Pubitemid 44232040)
117. Theocharides A., Boissinot M., Girodon F., et al. Leukemic blasts in transformed JAK2-V617F-positive myeloproliferative disorders are frequently negative for the JAK2-V617F mutation. Blood. 2007;110(1):375-379. (Pubitemid 47026857)
118. Moliterno A.R., Williams D.M., Rogers O., Isaacs M.A., Spivak J.L. Phenotypic variability within the JAK2 V617F-positive MPD: Roles of progenitor cell and neutrophil allele burdens. Exp Hematol. 2008;36(11):1480-1486.
119. James C., Mazurier F., Dupont S., et al. The hematopoietic stem cell compartment of JAK2V617Fpositive myeloproliferative disorders is a reflection of disease heterogeneity. Blood. 2008;112(6):2429-2438.
120. Stein B.L., Williams D.M., Rogers O., Isaacs M.A., Spivak J.L., Moliterno A.R. Disease burden at the progenitor level is a feature of primary myelofibrosis: A multivariable analysis of 164 JAK2 V617F-positive myeloproliferative neoplasm patients. Exp Hematol. 2011;39(1):95-101.
121. Sauvageau M., Sauvageau G. Polycomb group proteins: Multi-faceted regulators of somatic stem cells and cancer. Cell Stem Cell. 2010;7(3):299-313.
122. De Haan G., Gerrits A. Epigenetic control of hematopoietic stem cell aging the case of Ezh2. Ann N Y Acad Sci. 2007;1106:233-239. (Pubitemid 47443044)
123. Cao R., Zhang Y. The functions of E(Z)/EZH2-mediated methylation of lysine 27 in histone H3. Curr Opin Genet Dev. 2004;14(2):155-164. (Pubitemid 38520143)
124. Martinez-Garcia E., Licht J.D. Deregulation of H3K27 methylation in cancer. Nat Genet. 2010;42(2):100-101.
125. Viré E., Brenner C., Deplus R., et al. The Polycomb group protein EZH2 directly controls DNA methylation. Nature. 2006;439(7078):871-874. (Pubitemid 43255707)
126. Simon J.A., Lange C.A. Roles of the EZH2 histone methyltransferase in cancer epigenetics. Mutat Res. 2008;647(1-2):21-29.
127. Morin R.D., Johnson N.A., Severson T.M., et al. Somatic mutations altering EZH2 (Tyr641) in follicular and diffuse large B-cell lymphomas of germinal-center origin. Nat Genet. 2010;42(2):181-185.
128. Fisher C.L., Lee I., Bloyer S., et al. Additional sex combs-like 1 belongs to the enhancer of trithorax and polycomb group and genetically interacts with Cbx2 in mice. Dev Biol. 2010;337(1):9-15.
129. Scheuermann J.C., De Ayala Alonso A.G., Oktaba K., et al. Histone H2A deubiquitinase activity of the Polycomb repressive complex PR-DUB. Nature. 2010;465(7295):243-247.
130. Gelsi-Boyer V., Trouplin V., Adelaide J., et al. Mutations of polycomb-associated gene ASXL1 in myelodysplastic syndromes and chronic myelomonocytic leukaemia. Br J Haematol. 2009;145(6):788-800.
131. Abdel-Wahab O., Kilpivaara O., Patel J., Busque L., Levine R.L. The most commonly reported variant in ASXL1 (c. 1934dupG;p.Gly646TrpfsX12) is not a somatic alteration. Leukemia. 2010;24(9):1656-1657.
132. Fisher C.L., Pineault N., Brookes C., et al. Loss-offunction Additional sex combs like 1 mutations disrupt hematopoiesis but do not cause severe myelodysplasia or leukemia. Blood. 2010;115(1):38-46.
133. Ito S., D'Alessio A.C., Taranova O.V., Hong K., Sowers L.C., Zhang Y. Role of Tet proteins in 5mC to 5hmC conversion, ES-cell self-renewal and inner cell mass specification. Nature. 2010;466(7310):1129-1133.
134. Loenarz C., Schofield C.J. Oxygenase catalyzed 5-methylcytosine hydroxylation. Chem Biol. 2009;16(6):580-583.
135. Tahiliani M., Koh K.P., Shen Y., et al. Conversion of 5-methylcytosine to 5-hydroxymethylcytosine in mammalian DNA by MLL partner TET1. Science. 2009;324(5929):930-935.
136. Globisch D., Munzel M., Muller M., et al. Tissue distribution of 5-hydroxymethylcytosine and search for active demethylation intermediates. PLoS One. 2010;5(12):e15367.
137. Szwagierczak A., Bultmann S., Schmidt C.S., Spada F., Leonhardt H. Sensitive enzymatic quantification of 5-hydroxymethylcytosine in genomic DNA. Nucleic Acids Res. 2010;38(19):e181.
138. Song C.X., Szulwach K.E., Fu Y., et al. Selective chemical labeling reveals the genome-wide distribution of 5-hydroxymethylcytosine. Nat Biotechnol. 2011;29(1):68-72.
139. Koh K.P., Yabuuchi A., Rao S., et al. Tet1 and Tet2 regulate 5-Hydroxymethylcytosine production and cell lineage specification in mouse embryonic stem cells. Cell Stem Cell. 2011;8:200-213.
140. Lorsbach R.B., Moore J., Mathew S., Raimondi S.C., Mukatira S.T., Downing J.R. TET1, a member of a novel protein family, is fused to MLL in acute myeloid leukemia containing the t(10;11)(q22;q23). Leukemia. 2003;17(3):637-641. (Pubitemid 36395661)
141. Ono R., Taki T., Taketani T., Taniwaki M., Kobayashi H., Hayashi Y. LCX, leukemia-associated protein with a CXXC domain, is fused to MLL in acute myeloid leukemia with trilineage dysplasia having t(10; 11)(q22;q23). Cancer Res. 2002;62(14):4075-4080. (Pubitemid 34791077)
142. Ko M., Huang Y., Jankowska A.M., et al. Impaired hydroxylation of 5-methylcytosine in myeloid cancers with mutant TET2. Nature. 2010;468(7325):839-843.
143. Tefferi A., Pardanani A., Lim K.H., et al. TET2 mutations and their clinical correlates in polycythemia vera, essential thrombocythemia and myelofibrosis. Leukemia. 2009;23(5):905-911.
144. Schaub F.X., Looser R., Li S., et al. Clonal analysis of TET2 and JAK2 mutations suggests that TET2 can be a late event in the progression of myeloproliferative neoplasms. Blood. 2010;115(10):2003-2007.
145. Swierczek S.I., Yoon D, Bellanne'-Chantelot C, et al. Extent of hematopoietic involvement by TET2 mutations in JAK2V617F polycythemia vera. Haematologica. 2011;96(5)775-778.
146. Saint-Martin C., Leroy G., Delhommeau F., et al. Analysis of the ten-eleven translocation 2 (TET2) gene in familial myeloproliferative neoplasms. Blood. 2009;114(8):1628-1632.
147. Abdel-Wahab O., Manshouri T., Patel J., et al. Genetic analysis of transforming events that convert chronic myeloproliferative neoplasms to leukemias. Cancer Res. 2010;70(2):447-452.
148. Perna F., Gurvich N., Hoya-Arias R., et al. Depletion of L3MBTL1 promotes the erythroid differentiation of human hematopoietic progenitor cells: Possible role in 20q- polycythemia vera. Blood. 2010;116(15):2812-2821.
149. Ley T.J., Ding L., Walter M.J., et al. DNMT3A mutations in acute myeloid leukemia. N Engl J Med. 2010;363(25):2424-2433.
150. Kearney L., Gonzalez De Castro D., Yeung J., et al. Specific JAK2 mutation (JAK2R683) and multiple gene deletions in Down syndrome acute lymphoblastic leukemia. Blood. 2009;113(3):646-648.
151. Mullighan C.G., Zhang J., Harvey R.C., et al. JAK mutations in high-risk childhood acute lymphoblastic leukemia. Proc Natl Acad Sci U S A. 2009; 106(23):9414-9418.
152. Malinge S., Ben-Abdelali R., Settegrana C., et al. Novel activating JAK2 mutation in a patient with Down syndrome and B-cell precursor acute lymphoblastic leukemia. Blood. 2007;109(5):2202-2204. (Pubitemid 46348223)
153. Malinge S., Ragu C., Della-Valle V., et al. Activating mutations in human acute megakaryoblastic leukemia. Blood. 2008;112(10):4220-4226.
154. Boultwood J., Perry J., Pellagatti A., et al. Frequent mutation of the polycomb-associated gene ASXL1 in the myelodysplastic syndromes and in acute myeloid leukemia. Leukemia. 2010;24(5):1062-1065.
155. Plo I., Zhang Y., Le Couedic J.P., et al. An activating mutation in the CSF3R gene induces a hereditary chronic neutrophilia. J Exp Med. 2009;206(8):1701-1707.
156. Ding J., Komatsu H., Wakita A., et al. Familial essential thrombocythemia associated with a dominant-positive activating mutation of the c-MPL gene, which encodes for the receptor for thrombopoietin. Blood. 2004;103(11):4198- 4200. (Pubitemid 38685363)
157. Skoda RC. Thrombocytosis. Hematology Am Soc Hematol Educ Program. 2009;159-167.
158. De la Chapelle A., Sistonen P., Lehvaslaiho H., Ikkala E., Juvonen E. Familial erythrocytosis genetically linked to erythropoietin receptor gene. Lancet. 1993;341(8837):82-84. (Pubitemid 23028116)
159. De la Chapelle A., Traskelin A.L., Juvonen E. Truncated erythropoietin receptor causes dominantly inherited benign human erythrocytosis. Proc Natl Acad Sci U S A. 1993;90(10):4495-4499. (Pubitemid 23148931)
160. Prchal J.T., Sokol L. "Benign erythrocytosis" and other familial and congenital polycythemias. Eur J Haematol. 1996;57(4):263-268. (Pubitemid 26413118)
161. Sokol L., Luhovy M., Guan Y., Prchal J.F., Semenza G.L., Prchal J.T. Primary familial polycythemia: A frameshift mutation in the erythropoietin receptor gene and increased sensitivity of erythroid progenitors to erythropoietin. Blood. 1995;86(1):15-22.
162. Haeno H., Levine R.L., Gilliland D.G., Michor F. A progenitor cell origin of myeloid malignancies. Proc Natl Acad Sci U S A. 2009;106(39):16616-16621.
163. Vickers M.A. JAK2 617V>F positive polycythemia rubra vera maintained by approximately 18 stochastic stem-cell divisions per year, explaining age of onset by a single rate-limiting mutation. Blood. 2007;110(5):1675-1680. (Pubitemid 47443986)
164. Catlin S.N., Guttorp P., Abkowitz J.L. The kinetics of clonal dominance in myeloproliferative disorders. Blood. 2005;106(8):2688-2692. (Pubitemid 41510741)
165. Fung T.K., CheungA.M., Kwong Y.L., Liang R., LeungA.Y. Differential NOD/SCID mouse engraftment of peripheral blood CD34+ cells and JAK2V617F clones from patients with myeloproliferative neoplasms. Leuk Res. 2010;34(10):1390- 1394.
166. Ishii T., Zhao Y., Sozer S., et al. Behavior of CD34+ cells isolated from patients with polycythemia vera in NOD/SCID mice. Exp Hematol. 2007;35(11):1633-1640. (Pubitemid 47633770)
167. Van Pelt K., Nollet F., Selleslag D., et al. The JAK2V617F mutation can occur in a hematopoietic stem cell that exhibits no proliferative advantage: A case of human allogeneic transplantation. Blood. 2008;112(3):921-922.
168. Rongvaux A., Willinger T., Takizawa H., et al. Human thrombopoietin knockin mice efficiently support human hematopoiesis in vivo. Proc Natl Acad Sci U S A. 2011;108(6):2378-2383.
169. De Graaf C.A., Kauppi M., Baldwin T., et al. Regulation of hematopoietic stem cells by their mature progeny. Proc Natl Acad Sci U S A. 2010;107(50):21689-21694.
170. Kaushansky K. Thrombopoietin: Accumulating evidence for an important biological effect on the hematopoietic stem cell. Ann N Y Acad Sci. 2003;996:39-43. (Pubitemid 36706584)
171. Bumm T.G.P., VanDyke J., Loriaux M., et al. TNF-alpha plays a crucial role in the JAK2-V617F induced myeloproliferative disorder. Blood. 2007;110(11):675.
172. Jäger R., Kralovics R. Molecular pathogenesis of philadelphia chromosome negative chronic myeloproliferative neoplasms. Curr Cancer Drug Targets. 2011;11(1):20-30.
173. Beer P.A., Erber W.N., Campbell P.J., Green A.R. How we treat essential thrombocythemia. Blood. 2011;117(5):1472-1482.
174. Bocchia M., Vannucchi A.M., Gozzetti A., et al. Insights into JAK2-V617F mutation in CML. Lancet Oncol. 2007;8(10):864-865.
175. Bornhäuser M., Mohr B., Oelschlaegel U., et al. Concurrent JAK2(V617F) mutation and BCR-ABL translocation within committed myeloid progenitors in myelofibrosis. Leukemia. 2007;21(8):1824-1826. (Pubitemid 47086774)
176. Büsche G., Hussein K., Bock O., Kreipe H. Insights into JAK2-V617F mutation in CML. Lancet Oncol. 2007;8(10):863-864. (Pubitemid 47488061)
177. Cambier N., Renneville A., Cazaentre T., et al. JAK2V617F-positive polycythemia vera and Philadelphia chromosome-positive chronic myeloid leukemia: One patient with two distinct myeloproliferative disorders. Leukemia. 2008;22(7):1454-1455. (Pubitemid 352006095)
178. Hussein K., Bock O., Theophile K., et al. Biclonal expansion and heterogeneous lineage involvement in a case of chronic myeloproliferative disease with concurrent MPLW515L/JAK2V617F mutation. Blood. 2009;113(6):1391- 1392.
179. Lambert J.R., Everington T., Linch D.C., Gale R.E. In essential thrombocythemia, multiple JAK2-V617F clones are present in most mutant-positive patients: A new disease paradigm. Blood. 2009;114(14):3018-3023.
180. Couronné L., Lippert E., Andrieux J., et al. Analyses of TET2 mutations in post-myeloproliferative neoplasm acute myeloid leukemias. Leukemia. 2010;24(1):201-203.
181. Raaijmakers M.H., Mukherjee S., Guo S., et al. Bone progenitor dysfunction induces myelodysplasia and secondary leukaemia. Nature. 2010;464(7290):852-857.
182. Lataillade J.J., Pierre-Louis O., Hasselbalch H.C., et al. Does primary myelofibrosis involve a defective stem cell niche? From concept to evidence. Blood. 2008;112(8):3026-3035.
183. Landgren O., Goldin L.R., Kristinsson S.Y., Helgadottir E.A., Samuelsson J., Bjorkholm M. Increased risks of polycythemia vera, essential thrombocythemia, and myelofibrosis among 24,577 first-degree relatives of 11,039 patients with myeloproliferative neoplasms in Sweden. Blood. 2008;112(6):2199-2204.
184. Jones A.V., Chase A., Silver R.T., et al. JAK2 haplotype is a major risk factor for the development of myeloproliferative neoplasms. Nat Genet. 2009;41(4):446-449.
185. Olcaydu D., Harutyunyan A., Jager R., et al. A common JAK2 haplotype confers susceptibility to myeloproliferative neoplasms. Nat Genet. 2009;41(4):450-454.
186. Kilpivaara O., Mukherjee S., Schram A.M., et al. A germline JAK2 SNP is associated with predisposition to the development of JAK2(V617F)-positive myeloproliferative neoplasms. Nat Genet. 2009;41(4):455-459.
187. Jones A.V., Campbell P.J., Beer P.A., et al. The JAK2 46/1 haplotype predisposes to MPL-mutated myeloproliferative neoplasms. Blood. 2010;115(22):4517-4523.
188. Verstovsek S. Janus-activated kinase 2 inhibitors: A new era of targeted therapies providing significant clinical benefit for Philadelphia chromosomenegative myeloproliferative neoplasms. J Clin Oncol. 2011;29(7):781-783.
189. Verstovsek S., Kantarjian H., Mesa R.A., et al. Safety and efficacy of INCB018424, a JAK1 and JAK2 inhibitor, in myelofibrosis. N Engl J Med. 2010;363(12):1117-1127.
190. Tefferi A. How I treat myelofibrosis. Blood. 2011;117(13):3494-3504.
191. Tefferi A., Vainchenker W. Myeloproliferative neoplasms: Molecular pathophysiology, essential clinical understanding, and treatment strategies. J Clin Oncol. 2011;29(5):573-582.
192. Geron I., Abrahamsson A.E., Barroga C.F., et al. Selective inhibition of JAK2-driven erythroid differentiation of polycythemia vera progenitors. Cancer Cell. 2008;13(4):321-330. (Pubitemid 351446196)
193. .Wernig G., Kharas M.G., Okabe R., et al. Efficacy of TG101348, a selective JAK2 inhibitor, in treatment of a murine model of JAK2V617F-induced polycythemia vera. Cancer Cell. 2008;13(4):311-320. (Pubitemid 351446195)
194. Kiladjian J.J., Masse A., Cassinat B., et al. Clonal analysis of erythroid progenitors suggests that pegylated interferon alpha-2a treatment targets JAK2V617F clones without affecting TET2 mutant cells. Leukemia. 2010;24(8):1519-1523.
195. .Wang Y., Fiskus W., Chong D.G., et al. Cotreatment with panobinostat and JAK2 inhibitor TG101209 attenuates JAK2V617F levels and signaling and exerts synergistic cytotoxic effects against human myeloproliferative neoplastic cells. Blood. 2009;114(24):5024-5033.
196. Rambaldi A., Dellacasa C.M., Finazzi G., et al. A pilot study of the Histone-Deacetylase inhibitor Givinostat in patients with JAK2V617F positive chronic myeloproliferative neoplasms. Br J Haematol. 2010;150(4):446-455.
197. .Wang X., Zhang W., Ishii T., et al. Correction of the abnormal trafficking of primary myelofibrosis CD34+cells by treatment with chromatin-modifying agents. Cancer Res. 2009;69(19):7612-7618.
198. .Wang X., Zhang W., Tripodi J., et al. Sequential treatment of CD34+ cells from patients with primary myelofibrosis with chromatin-modifying agents eliminate JAK2V617F-positive NOD/SCID marrow repopulating cells. Blood. 2010;116(26):5972-5982.